https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Keros_Therapeutics%2C_Inc.Keros Therapeutics, Inc. - Revizia istoricului2026-04-04T22:31:22ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Keros_Therapeutics,_Inc.&diff=427667&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Keros Therapeutics, Inc. listata cu simbolul US.KROS ==Descriere companie== Keros Therapeutics, Inc. (www.kerostx.com) is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood...2024-09-18T18:08:16Z<p>Pagină nouă: Pagina dedicata companiei Keros Therapeutics, Inc. listata cu simbolul US.KROS ==Descriere companie== Keros Therapeutics, Inc. (www.kerostx.com) is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Keros Therapeutics, Inc. listata cu simbolul US.KROS<br />
<br />
==Descriere companie==<br />
Keros Therapeutics, Inc. (www.kerostx.com) is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. Its small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressive (FOP), a musculoskeletal disorder. Its third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension (PAH).<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.KROS" /><br />
<br />
==Ultimele stiri despre Keros Therapeutics, Inc. (US.KROS)==<br />
<dynamicpagelist><br />
category=US.KROS<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.KROS]][[Categorie:Stiri despre companii]]</div>Admin